IL33 and cancer: Hypoxia and tissue damage, common in rapidly growing tumours, promote passive IL-33 release from necrotic stromal/epithelial cells and activate stromal cancer associated fibroblasts (CAFs), which can amplify IL-33 production and secrete chemokines that recruit Tregs and MDSCs [98].